T2 Biosystems Announces Changes to Board of Directors

LEXINGTON, Mass., June 15, 2020 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced three new Board of Director appointments. The three new directors will add significant clinical and commercialization experience and expand board diversity, coupled with a strong understanding of the Company’s customer base.

The new appointments include: Thierry Bernard, Chief Executive Officer, QIAGEN; Dr. Ninfa Saunders, President and Chief Executive Officer, Navicent Health; and Robin Toft, Founder and Chief Executive Officer, Toft Group, a ZRG company.

“We are thrilled to add to our Board three individuals whose commercial expertise and combined background in molecular diagnostics, clinical care, and life science leadership will bring invaluable perspective and insight to our business, helping us to achieve our goals of accelerating our sales, improving our operations, and advancing our pipeline,” said John Sperzel, President and Chief Executive Officer, T2 Biosystems. “Our commitment to developing innovative technology that helps save lives and improve patient outcomes remains steadfast, and adding these three industry leaders will bolster our efforts to accomplish that in the coming months and years.”

Thierry Bernard is the CEO at QIAGEN. Mr. Bernard joined QIAGEN in February 2015 to lead QIAGEN’s growing presence in molecular diagnostics.  Mr. Bernard previously held multiple roles at bioMerieux for fifteen years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMerieux, he served in management roles in multiple international environments. Mr. Bernard is a member of the Board of Directors of First Light Biosciences. He has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics and the College of Europe, and is a member of French Foreign Trade Advisors.

Dr. Ninfa M. Saunders, FACHE, is the President and CEO of Navicent Health, the second largest hospital in Georgia and a tertiary regional teaching medical center. Dr. Saunders has more than 45 years of hospital administrative and clinical experience, and prior to her current role, served as the President and COO of Virtua Health, the largest health system in southern New Jersey. Dr. Saunders was recognized by Modern Healthcare as one of 2019’s Top 25 Women Leaders in the U.S. and was twice named one of the “Most Influential Women of the Mid-Market” in the U.S. by CEO Corporation. Dr. Saunders serves on the boards of the Georgia Hospital Association and the American Hospital Association, where she is the past chair for the Institute for Diversity. Dr. Saunders completed her Doctorate in Healthcare Administration at the Medical University of South Carolina, earned a Master’s of Business Administration from Emory University, and a Master of Science in Nursing from Rutgers University.

Robin Toft is the founder and CEO of Toft Group, a ZRG company, where she combines a deep inside knowledge of the life science industry with a passion for building game-changing management teams. Ms. Toft has placed hundreds of executives at innovation-led life science companies. A champion of diverse executive teams, she has built a reputation for recruiting women and minorities into C-level and board of director roles. Prior to founding Toft Group in 2010, Ms. Toft served 20+ years as a biotech executive, most recently as Senior Vice President, Commercial Operations at Roche Molecular Diagnostics. In the 2020 American Business Awards, Ms. Toft received three Gold awards for Lifetime Achievement, Maverick of the Year and Woman of the Year.  She currently serves on The Clearity Foundation board for ovarian cancer care, and is Chairman of LEAD San Diego, dedicated to developing civically engaged leaders. Ms. Toft earned a Bachelor of Science from Michigan State University.

Along with these additions, the Company announced the departure of three long-standing board members: Michael Cima, Ph.D., Adrian M. Jones, and Stanley Lapidus.

“We are profoundly grateful for the passion, ingenuity and leadership exhibited by the departing board members over the past several years,” said John McDonough, Chairman of the Board of Directors, T2 Biosystems. “Their collective contributions have made a significant and lasting impact on the Company, for which we will remain forever grateful.”

The new board members will join the following existing board members:

  • John Sperzel, President and CEO, T2 Biosystems
  • John McDonough, Chairman of the Board, T2 Biosystems
  • John W. Cumming, Former Chairman and CEO, Hologic
  • David Elsbree, Former Senior Partner, Deloitte & Touche
  • Seymour Liebman, Executive Vice President, Chief Administrative Officer and General Counsel of Canon U.S.A, Inc.; Senior Managing Executive Officer of Canon Inc., Japan; and Vice Chairman, Canon Solutions America, Inc.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, and the T2Resistance™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, T2SARS-CoV-2™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, as well as biothreat pathogens.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding growth in the Company’s sales, improvement in operations, and pipeline advancement, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials;  (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, and other filings the Company makes with the SEC from time to time.  These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.  These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Media Contact:
Gina Kent, Vault Communications

Investor Contact:
Philip Trip Taylor, Gilmartin Group

Robin Toft, Founder/CEO, Toft Group Executive Search Wins Three Gold American Business Awards Maverick of Year – Woman of Year – Lifetime Achievement

Robin Toft, the Founder and CEO of Toft Group, a leading executive search firm fully devoted to life sciences and healthcare, won Gold, the top award, in the American Business Awards for 2020. Toft won in three categories: Maverick of the Year; Woman of the Year and Lifetime Achievement – all in Business Services Industries.

Winners were announced on Monday May 18th, 2020. This year, a total of 3,600 companies/entrepreneurs entered the awards; the American Business Award competition is one of the top two business awards in the U.S. The awards will be presented in a special virtual ceremony on August 5, 2020, replacing a gala that was originally scheduled at the Marriot Marquis Hotel in New York City. 

Toft won Gold for leading Toft Group, an executive search firm playing a key role in placing top talent researching a cure for Covid-19; for her focus on diversity including a 98% women-on-boards placement rate in 2019, which is five times the national average; and a 48% placement rate for women in senior level positions (Catalyst reports 29% of senior management roles held by women in 2019); and for Toft Group’s speed to placement.  

In February of 2019, the awards “year,” Toft published a diversity-based book titled WE CAN, The Executive Woman’s Guide to Career Advancement. Inspired by Toft’s personal experience as a career executive, coupled with her first-hand observation that most female executives are “miserable” in their careers, the book is a bold blueprint for what’s needed: decisiveness; discipline; a career map; confidence; and the “power” to create professional value and ask for opportunities throughout your career. In 2019, Toft has mentored 1000s of women free-of-charge to assist them in building careers that matter to them, both professionally and personally.

The nomination included keynote addresses for major corporations, non-profit organizations and universities, including Qualcomm; Illumina; the top conferences for next -gen women leaders as well as in biotech and precision medicine.

For the Lifetime Achievement award in particular, Toft’s contributions in healthcare and biotech as a top executive for 20 years, working in virology and diagnostics, before starting her company ten years ago, played a part. These included launching the first global initiative to provide access to HIV testing during the early days of the HIV/ AIDS pandemic; and launching and commercializing the first HIV/AIDS genotype and phenotype test to guide doctors in making correct drug combinations. The latter was key in HIV becoming a chronic disease and no longer a fatal one.

In 2020, Toft turned WE CAN into a start-up company aimed at helping women – and men – “grow from the ‘outside IN.’” 

About Toft Group Executive Search, a ZRG Company:   

Toft Group, headquartered in San Francisco, is an executive search firm focused on innovation-driven companies at the intersection of biotech and high tech. In November 2019, Toft Group, was acquired by ZRG Partners, a global executive search firm. Toft Group’s WE CAN™ (Women’s Executive Career Advancement Network) and extensive track record of performance has proven its ability to quickly fill highly specialized leadership roles where talent is limited. For more information, please visit thetoftgroup.com.

With Women Needed At Highest Levels Of Brokerage, Pressure Is On To Build The Talent Pipeline

Now Hiring: Senior Associate

ZRG Rolls Out a Game-Changing Way to Assess Culture Fit in Hiring

ZRG Acquires Toft Group, a Leader in Life Sciences and Biotech Recruiting

ROCHELLE PARK, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) — ZRG, the fastest growing global executive search firm, today announced that it has acquired the Toft Group, a market leader in the placement of Life Science and Biotech leadership.

The business will operate as a ZRG company, focused on supporting client needs for senior life science professionals and will add depth to the existing global Life Sciences practice at ZRG.

The transaction will add approximately $10 million in annual revenues to ZRG and bolster the firm’s direct presence in the Global Life Science sector in which it maintains a strong market presence in the top tier Pharma space. With this acquisition, ZRG will report revenues anticipated to exceed $65 Million in 2019 and will have over 200 team members globally to support clients in important executive recruiting and talent solutions work.

The Toft Group has a sector focus in working with early stage life science with a special niche in innovation-driven companies at the intersection of biotech and high tech. Additionally, the Toft Group has a strong reputation for actively promoting diversity in recruiting. Robin Toft, founder and chair of the company, is also the author of WeCan, a holistic look at preparing diverse leaders for productive career as executives and board members.

“The Toft Group is the market leader for early stage biotech and life science recruiting. They have built a stellar track record in bringing top talent to their clients, quickly,” said Larry Hartmann, CEO of ZRG. “Combining their sector expertise with the extensive work ZRG is already doing with our 12 life science consultants creates a strong global Life Science practice.  We are thrilled to add Robin to our executive team and welcome the entire Toft Group to the ZRG family.”

“This is the ideal next chapter for our firm. The ability to now expand our offerings globally and broaden our offerings working side by side with the ZRG team will allow us to partner at an even deeper level with our client base,” Robin Toft said. “The functional expertise of ZRG, combined with our sector knowledge and local presence in important West Coast markets, will further define us as the ‘go to’ firm for all life science work.”

“ZRG’s data-driven, tech-enabled search process and its digital platform will even further speed up our ability to service our client base,” Toft added. “We look forward to continuing to grow our business sector and expand our relationships with our ZRG colleagues, who do significant executive search work at the most senior levels.”

Robin Toft will continue in her role as Founder & Chair of the Toft Group in order to build out the business and help with the overall growth of ZRG as a senior leader.

Objective Capital Partners acted as the financial advisor to the Toft Group.

About Toft Group
Founded in 2010, the Toft Group is one of the world largest boutique early stage life science recruiting firms Headquartered in San Francisco, CA, with branch offices in San Diego and Boston. The Toft Group has been recognized as a Top 50 recruiting firm in the America’s by Hunt Scanlon, and Robin Toft was recognized in 2018 and 2019 as finalist for the prestigious EY Entrepreneur of the Year award.

About ZRG

Since 1999, ZRG’s data-driven approach to executive and professional search has been changing the way clients think about how to find top talent. Today, ZRG is one of the fastest growing firms in the search industry and provides a full suite of executive, middle management, project, and interim search solutions globally through its offices in North America, Europe, South America, and Asia.

ZRG’s sole focus is to match clients with the right leaders. Leveraging technological innovation, years of experience, and our ability to identify quality candidates, Strong leadership effectively steers the ship of a company. It’s not uncommon for businesses to falter under sub-par leadership; that’s where ZRG comes into play by helping firms identify and hire the right leaders. ZRG’s analytical process and collaborative culture give us the competitive advantage to provide our clients with the industry advantage.

Media Contact: John Mooney, Over The Moon PR, (908) 720-6057, john@overthemoonpr.com

Toft Group Welcomes Julie Visser as Executive Career Coach and Executive Search Leader

Toft Group Executive Search, a global life sciences and healthcare executive recruiting firm, announced Julie Visser has been appointed as Toft Group’s Executive Career Coach and Executive Search Leader. Ms. Visser has more than 20 years of expertise in talent acquisition, executive C-Suite placements and executive career coaching. She will oversee Toft Group’s corporate executive career coaching initiative and continue to build executive search assignments for both C-Suite talent and Board member positions. 

“Demand for top talent, particularly qualified diverse candidates, is at an all-time high as healthcare companies recognize a talent gap has emerged, and companies recognize the competitive advantage of an inclusive executive team complimented by an inclusive Board of Directors,” said Ron Giannotti, President and CEO of Toft Group.  “I am thrilled with the addition of Julie’s talent to our Toft Team! Her knowledge will play a key role in expanding our life science executive search practice. In addition, Julie brings the experience and know-how to build a premier coaching practice which is a key component of the soon to be released WE CAN™ Platform that enables female candidates to prepare and accelerate their careers.”

Prior to joining Toft Group, Ms. Visser enjoyed a career leading and partnering with US companies’ worldwide human resource efforts, including Life Technologies, Thermo Fisher and NuVasive. Her expertise in talent acquisition and executive global placement has resulted in countless job opportunities for those seeking advancement in their careers. In addition, Ms. Visser is the founder of JA Talent Partners, a career coaching company, focused on women re-entering the workforce.  

Ms. Visser holds a bachelor’s degree in marketing management from the University of Arizona and is AIRS certified.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies at the intersection of biotech and high tech. Toft Group’s targeted, accurate searches translate into exceptional return-on-investment for clients nationwide, and the team’s extensive networks enable the presentation of more highly qualified and diverse candidates than clients would otherwise see. The firm’s extensive track record has shown its ability to quickly fill highly specialized leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Diego, San Francisco and Boston.

Toft Group Executive Search Places Ellen Lubman on Board of Advisors at TMRW Life Sciences, Inc. in New York, NY

Toft Group Executive Search, a global life sciences and healthcare executive recruiting firm, has successfully placed Ellen Lubman on Board of Advisors at TMRW Life Scienc

As Chief Business Officer of Impel Neuropharma, Ms. Lubman leads corporate development activities and strategy for the private neuroscience therapeutics company.

Prior to joining Impel, she served as the Vice President of External Science & Innovation at Allergan, where she was responsible for strategic expansion of the company’s pipeline in a variety of disease areas, including women’s health. 

“We are thrilled to have Ellen join our Advisory Board,” said Alan Murray, TMRW’s Founder and Co-CEO. “Her deep interest in and understanding of the assisted reproductive technology landscape and her experience as a senior leader at life sciences companies at every stage of development make her an ideal advisor for TMRW, especially regarding strategic partnering and financing initiatives.”

Ms. Lubman has 20 years of biopharmaceutical corporate development and Wall Street industry experience, including roles at Kadmon Pharmaceuticals, Bristol-Myers Squibb, Celtic Pharma Management, L.P. and Robertson Stephens. She is a member of the Board of Directors of Dauntless Pharmaceuticals and GeneCentric Therapeutics.

About TMRW

In coming decades, a rapidly scaling fertility industry and increased access to IVF therapies will be responsible for nearly 300 million global births — almost all of which will rely upon frozen fertility cells. To meet this rapidly growing demand, TMRW has created the first fully Robotic Process Automation (RPA) platform designed specifically for IVF. Already experiencing rapid market adoption, TMRW is poised to become the global standard for cryo-preservation and fertility cell management. IVF clinicians have embraced TMRW’s RPA platform because it replaces an outdated analog IVF cryo-management function with proven risk-mitigating Robotic Process Automation technology.

TMRW provides the world’s first complete RFID cryo-temperature compatible digital chain of custody for all fertility cells—including embryos and gametes. TMRW software is constantly vigilant and automates 17,000 daily environmental “health checks” that ensure the safety and security of the world’s most precious cells.

TMRW’s co-founders, Joshua Abram, Alan Murray and Dr. Jeff Port, are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Executive Search Places Chris Cournoyer on Board of Directors for CareDx, Inc. in Brisbane, CA

Toft Group Executive Search, a global life sciences and healthcare executive recruiting firm, has successfully placed Chris Cournoyer on the Board of Directors for CareDx, Inc. in Brisbane, CA. 

“Chris brings deep experience in technology and her recent experiences with EHR and CDS solutions will be invaluable,” comments Peter Maag, CareDx Chief Executive Officer, “as we build out our offerings in Digital Transplant Solutions.”

Cournoyer was previously the Chairperson and Chief Executive Officer for N-of-One. N-of-One is a leader in precision medicine delivering clinical and molecular decision support for targeted therapies decisions based on a cancer patient’s molecular profile. Prior, she was the Vice President of Clinical Analytics at Optum, through the acquisition of Picis where she was the President and COO. At Optum and Picis, Cournoyer was responsible for clinical EHR solutions and clinical decision support (CDS) solutions. Cournoyer has also held roles at Harte Hanks, Lotus, and IBM. At Lotus she was the Chief Information Officer. At IBM she was Vice President of Global Business Transformation responsible for driving the digital strategy for global software fulfillment for the $8B software business. 

Ron Giannotti, President and CEO of Toft Group said: “CareDx is an exceptionally innovative company with an incredibly strong leadership team.  Chris will add significant value to the organization, and will be a strong contributor to the future growth of the company.”

She has provided technology expertise and guidance on the digital strategy for three public boards including Stride Rite, GTECH, and BJ’s Wholesale group, and has been a director for Emerson Hospital. Cournoyer holds a B.S in Business Administration, University of Massachusetts, an MA in Economics, Northeastern University and has attended MIT ‘s Executive Education Program.

“I look forward to bringing my experiences to impact care for transplant patients. CareDx is well positioned to be the data leader in transplant, and I am excited to join the board working closely with the management team to positively impact patients’ lives,” said Chris Cournoyer.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.